GameSpot may get a commission from retail offers. The month of December is a busy one for Arc Raiders. The major highlight of the month is the Cold Snap update, which introduces a slew of content to ...
You can trust VideoGamer. Our team of gaming experts spend hours testing and reviewing the latest games, to ensure you're reading the most comprehensive guide possible. Rest assured, all imagery and ...
The price for choosing an inflatable kayak is usually performance. But Advanced Elements believes they've created a high performing inflatable kayak that is fun to paddle, stable enough for beginners, ...
Mr. Giridharadas is the author of “Winners Take All: The Elite Charade of Changing the World” and the publisher of the newsletter The.Ink. As journalists comb through the Epstein emails, surfacing the ...
Expeditions are ARC Raiders' take on resetting your account, also called a wipe or a prestige. The mechanic is a core tenet of progression in extraction shooters, and ARC not only has a lengthy list ...
The Blue Oval is eager to capture sales from Chevrolet. It’s clear that significant time, effort, and investment were put into the 2025 Ford Expedition to help it steal some sales away from the Chevy ...
If you had told me that a debut double-A game from a studio of largely unknown developers would be one of the biggest contenders for the Game of the Year awards in 2025, as well as one of the best ...
Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a ...
GameSpot may get a commission from retail offers. Sandfall Interactive's Clair Obscur: Expedition 33 came out of nowhere on its way to becoming one of 2025's breakout success stories. Now, Sandfall ...
Forget the small family haulers. Leave the keys to your midsize SUV at home. Got one of those puny crossovers? Punt it towards the goal posts. In Expedition town, there's no room for small fries. The ...
XH-S004 is being studied for its efficacy against non-cystic fibrosis bronchiectasis in Phase II trials and COPD in Phase Ib trials. Credit: Shanghai Fosun Pharmaceutical (Group)Co, Ltd. Fosun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback